

Immunization Safety Office Updates

Centers for Disease Control and Prevention

Tom Shimabukuro, MD, MPH, MBA

Immunization Safety Office

Division of Healthcare Quality Promotion

National Center for Emerging and Zoonotic Infectious Diseases

Centers for Disease Control and Prevention (CDC)

Advisory Commission on Childhood Vaccines (ACCV)

March 7, 2013

National Center for Emerging and Zoonotic Infectious Diseases

Division of Healthcare Quality Promotion – Immunization Safety Office



Topics

- ❑ **February 2014 Advisory Committee on Immunization Practices (ACIP) meeting vaccine safety presentations**
- ❑ **Princeton University and University of California, Santa Barbara serogroup B meningococcal vaccine programs**
- ❑ **Selected publications**

February 2014 ACIP meeting vaccine safety presentations

❑ Influenza session

- Interim influenza vaccine safety update: LAIV and IIV in persons <18 years of age
- Safety of LAIV vs. IIV for healthy children (GRADE)

❑ Safety of tetanus, diphtheria, and acellular pertussis (Tdap) vaccine session

- Safety of Tdap vaccine during pregnancy: enhanced surveillance in VAERS
- Tdap during pregnancy: safety and coverage data from the VSD

❑ February 2014 ACIP meeting summary will be provided at next ACCV meeting

Serogroup B meningococcal vaccine programs

- ❑ Prolonged outbreaks of serogroup b meningococcal disease are occurring at Princeton University and University of California, Santa Barbara
- ❑ Serogroup b meningococcal disease is serious and potentially fatal
- ❑ CDC is currently working with these institutions, public health agencies and the FDA to coordinate vaccination programs with serogroup B meningococcal vaccine
- ❑ The vaccine (Bexsero) is not licensed in the US and is being given under an Expanded Access to Investigational New Drug drug protocol approved by FDA
- ❑ For more information refer to CDC website at <http://www.cdc.gov/meningococcal/outbreaks/vaccine-serogroupB.html>

Selected publications

- ❑ **Stockwell et al. Risk of Fever After Pediatric Trivalent Inactivated Influenza Vaccine and 13-Valent Pneumococcal Conjugate Vaccine. JAMA Pediatr. 2014 Jan 6. [Epub ahead of print]**
 - **Simultaneous TIV and PCV13 administration was associated with higher transient increased fever risk than administration of either vaccine without the other product**
- ❑ **Moro et al. Reports to the Vaccine Adverse Event Reporting System after hepatitis A and hepatitis AB vaccines in pregnant women. Am J Obstet Gynecol. 2013 Dec 27. [Epub ahead of print]**
 - **This review of VAERS reports did not identify any concerning pattern of AEs in pregnant women or their infants following maternal Hep A or Hep AB immunizations during pregnancy**

Selected publications

- **Vellozzi et al. Guillain-Barre Syndrome, Influenza, and Influenza Vaccination: The Epidemiologic Evidence. Clin Infect Dis. 2014 Feb 5. [Epub ahead of print]**
 - **A small increased risk of Guillain-Barré syndrome (GBS) has been observed following influenza vaccines but 10-fold less than that observed following the 1976 swine-influenza vaccine**
 - **The risk of GBS following influenza is much greater than the small risk following vaccination.**

- **Hibbs et al. Notes from the field: rotavirus vaccine administration errors - United States, 2006-2013. MMWR Morb Mortal Wkly Rep. 2014 Jan 31;63(4):81.**
 - **CDC identified 39 reports of rotavirus vaccine administration by injection in VAERS and 27 reports of eye splashes**
 - **Administration errors are largely preventable with proper education and training**

Selected publications

- **Vellozzi et al. Cumulative Risk of Guillain-Barré Syndrome Among Vaccinated and Unvaccinated Populations During the 2009 H1N1 Influenza Pandemic. Am J Public Health. 2014 Feb 13. [Epub ahead of print]**
 - **Cumulative GBS risk was less among the pH1N1vaccinated than the unvaccinated population, suggesting the benefit of vaccination as it relates to GBS**
 - **The observed potential protective effect on GBS attributed to vaccination warrants further study**



Centers for Disease Control and Prevention Atlanta, GA

National Center for Emerging and Zoonotic Infectious Diseases
Division of Healthcare Quality Promotion – Immunization Safety Office



Thank You

For more information please contact Centers for Disease Control and Prevention

1600 Clifton Road NE, Atlanta, GA 30333

Telephone, 1-800-CDC-INFO (232-4636)/TTY: 1-888-232-6348

E-mail: cdcinfo@cdc.gov

Web: www.cdc.gov

The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.

National Center for Emerging and Zoonotic Infectious Diseases

Division of Healthcare Quality Promotion – Immunization Safety Office

